PI3K regulates TAZ/YAP and mTORC1 axes that can be synergistically targeted
Authors:
- Keith C. GarciaKGKeith C. Garcia
- Ali A. KhanAKAli A. Khan
- Krishnendu GhoshKGKrishnendu Ghosh
- Souradip SinhaSSSouradip Sinha
- Nicholas ScaloraNSNicholas Scalora
- Gillian DeWaneGDGillian DeWane
- Colleen FullenkampCFColleen Fullenkamp
- Nicole MerrittNMNicole Merritt
- Yuliia DrebotYDYuliia Drebot
- Samuel Y. YuSYSamuel Y. Yu
- Mariah LeidingerMLMariah Leidinger
- Michael D. HenryMHMichael D. Henry
Open Access
- 10 February 2026
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (6)
Abstract
Sarcomas are a heterogeneous group of cancers with few shared therapeutic targets. We show that PI3K signaling is frequently activated in sarcomas due to PTEN loss (in 30-60%), representing a common therapeutic target. The PI3K pathway has lacked a downstream oncogenic transcription factor. We show TAZ and YAP are transcriptional co-activators regulated by PI3K and drive a transcriptome necessary for tumor growth in a PI3K-driven sarcoma mouse model. This PI3K-TAZ/YAP axis exists in parallel to the known PI3K-Akt-mTORC1 axis providing a rationale for combination therapy targeting the TAZ/YAP-TEAD interaction and mTORC1. Combination therapy using IK-930 (TEAD inhibitor) and everolimus (mTORC1 inhibitor) synergistically diminished proliferation and anchorage dependent growth of PI3K-activated sarcoma cell lines at low, physiologically achievable doses. Furthermore, this combination therapy showed a synergistic effect in vivo, suggesting that an integrated view of PI3K and Hippo signaling can be leveraged therapeutically in PI3K activated sarcomas.Keywords
All Related Versions
Funding Information
- Instituto Nacional de Cancerología (1 R01 CA237031-01A1)
- Veterans Health Administration Merit Review Program (1 I01 BX003644-01)
- Instituto Nacional de Cancerología (P30 CA086862)
This publication has 122 references indexed in Scilit:
- FGFR1 fusions as a novel molecular driver in rhabdomyosarcomaGenes, Chromosomes and Cancer, 2024
- A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumorsPediatric Blood & Cancer, 2019
- NPRL2 enhances autophagy and the resistance to Everolimus in castration‐resistant prostate cancerThe Prostate, 2018
- Systematic Functional Annotation of Somatic Mutations in CancerCancer Cell, 2018
- Novel YAP1‐TFE3 fusion defines a distinct subset of epithelioid hemangioendotheliomaGenes, Chromosomes and Cancer, 2013
- Dual Pten/Tp53 Suppression Promotes Sarcoma Progression by Activating Notch SignalingThe American Journal of Pathology, 2013
- Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor SignalingCell, 2012
- A novel WWTR1‐CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sitesGenes, Chromosomes and Cancer, 2011
- Elucidation of a Universal Size-Control Mechanism in Drosophila and MammalsCell, 2007
- Mechanism of activation of protein kinase B by insulin and IGF‐1.The EMBO Journal, 1996